Willem Vreuls

Willem Vreuls

Auto-generated profile, based on publicly available information

Willem Vreuls

Department of Pathology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Histopathology
Verified
Journal Article
Open access
RARicardo Almeida‐Magana
Ricardo Almeida‐Magana
MAMatthew Au
Matthew Au
TATarek Al‐Hammouri
Tarek Al‐Hammouri
MMManju Mathew
Manju Mathew
KDKate Dinneen
Kate Dinneen
AHAiman Haider
Aiman Haider
Introduction and objectives: Fluorescence confocal microscopy (FCM) is a new imaging modality capable of generating digital microscopic resolution scans of fresh surgical specimens, and holds potential as an alternative to frozen section (FS) analysis for intra‐operative assessment of surgical margins. Previously, we described the LaserSAFE technique as an application of FCM for margin assessment in robot‐assisted radical prostatectomy (RARP) using the Histolog® scanner. This study describes the accuracy and inter‐rater agreement of FCM imaging compared to corresponding paraffin‐embedded analysis (PA) among four blinded pathologists for the presence of positive surgical margins (PSM).Materials and methods: RARP specimens from patients enrolled in the control arm of the NeuroSAFE PROOF study (NCT03317990) were analysed from April 2022 to February 2023. Prostate specimens were imaged using the Histolog® scanner before formalin fixation and PA. Four trained assessors, blinded to PA, reviewed and analysed FCM images of the posterolateral prostatic surface.Results: A total of 31 prostate specimens were included in the study. PA per lateral side of the prostate identified 11 instances of positive margins. Among the four histopathologists included in our study, FCM achieved a sensitivity of 73–91 and specificity of 94–100% for the presence of PSM. Fleiss’ Kappa for inter‐rater agreement on PSM was 0.78 (95% confidence interval = 0.64–0.92), indicating substantial agreement.Conclusion: This blinded analysis of FCM versus PA among histopathologists with different experience levels demonstrated high accuracy and substantial inter‐rater agreement for diagnosing PSM. This supports the role of the FCM as an alternative to FS.

1 June 2021 in Lung Cancer
Verified
Journal Article
Closed access
MVM.P.J. Visser
M.P.J. Visser
IGI. van Grimbergen
I. van Grimbergen
JHJ. Hölters
J. Hölters
WBW.B. Barendregt
W.B. Barendregt
LVL.C. Vermeer
L.C. Vermeer
JJJ. Janssen
J. Janssen

1 August 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
WSW.B.G. Sanderink
W.B.G. Sanderink
Marco CaballoMarco Caballo
Marco Caballo
LSL.J.A. Strobbe
L.J.A. Strobbe
PBP. Bult
P. Bult
WVW. Vreuls
W. Vreuls
RMR.M. Mann
R.M. Mann

6 March 2024 in ESMO Open
Verified
Journal Article
Open access
LBL.W. de Boo
L.W. de Boo
KJK. Jóźwiak
K. Jóźwiak
NHN.D. Ter Hoeve
N.D. Ter Hoeve
PDPaul J van Diest
Paul J van Diest
MOM. Opdam
M. Opdam
SLSabine C. Linn
Sabine C. Linn
In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment de-escalation or escalation could be considered remains an unmet need. We evaluated the prognostic value of histopathologic traits in a unique cohort of young, (neo)adjuvant chemotherapy-naïve patients with early-stage (stage I or II), node-negative TNBC and long-term follow-up, in relation to stromal tumor-infiltrating lymphocytes (sTILs) for which the prognostic value was recently reported. We studied all 485 patients with node-negative eTNBC from the population-based PARADIGM cohort which selected women aged <40 years diagnosed between 1989 and 2000. None of the patients had received (neo)adjuvant chemotherapy according to standard practice at the time. Associations between histopathologic traits and breast cancer-specific survival (BCSS) were analyzed with Cox proportional hazard models. With a median follow-up of 20.0 years, an independent prognostic value for BCSS was observed for lymphovascular invasion (LVI) [adjusted (adj.) hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.49-3.69], fibrotic focus (adj. HR 1.61, 95% CI 1.09-2.37) and sTILs (per 10% increment adj. HR 0.75, 95% CI 0.69-0.82). In the sTILs <30% subgroup, the presence of LVI resulted in a higher cumulative incidence of breast cancer death (at 20 years, 58%; 95% CI 41% to 72%) compared with when LVI was absent (at 20 years, 32%; 95% CI 26% to 39%). In the ≥75% sTILs subgroup, the presence of LVI might be associated with poor survival (HR 11.45, 95% CI 0.71-182.36, two deaths). We confirm the lack of prognostic value of androgen receptor expression and human epidermal growth factor receptor 2 -low status. sTILs, LVI and fibrotic focus provide independent prognostic information in young women with node-negative eTNBC. Our results are of importance for the selection of patients for de-escalation and escalation trials.

30 October 2023 in European Journal of Cancer
Verified
Journal Article
Open access
YWYuwei Wang
Yuwei Wang
ABAnnegien Broeks
Annegien Broeks
DGDaniele Giardiello
Daniele Giardiello
MHMichael Hauptmann
Michael Hauptmann
KJKatarzyna Jóźwiak
Katarzyna Jóźwiak
Marjanka SchmidtMarjanka Schmidt
Marjanka Schmidt
The validity of the PREDICT breast cancer prognostic model is unclear for young patients without adjuvant systemic treatment. This study aimed to validate PREDICT and assess its clinical utility in young women with node-negative breast cancer who did not receive systemic treatment. We selected all women from the Netherlands Cancer Registry who were diagnosed with node-negative breast cancer under age 40 between 1989 and 2000, a period when adjuvant systemic treatment was not standard practice for women with node-negative disease. We evaluated the calibration and discrimination of PREDICT using the observed/expected (O/E) mortality ratio, and the area under the receiver operating characteristic curve (AUC), respectively. Additionally, we compared the potential clinical utility of PREDICT for selectively administering chemotherapy to the chemotherapy-to-all strategy using decision curve analysis at predefined thresholds. A total of 2264 women with a median age at diagnosis of 36 years were included. Of them, 71.2% had estrogen receptor (ER)-positive tumors and 44.0% had grade 3 tumors. Median tumor size was 16 mm. PREDICT v2.2 underestimated 10-year all-cause mortality by 33% in all women (O/E ratio:1.33, 95%CI:1.22-1.43). Model discrimination was moderate overall (AUC10-year:0.65, 95%CI:0.62-0.68), and poor for women with ER-negative tumors (AUC10-year:0.56, 95%CI:0.51-0.62). Compared to the chemotherapy-to-all strategy, PREDICT only showed a slightly higher net benefit in women with ER-positive tumors, but not in women with ER-negative tumors. PREDICT yields unreliable predictions for young women with node-negative breast cancer. Further model updates are needed before PREDICT can be routinely used in this patient subset.

15 February 2017 in Cancer Research
Verified
Journal Article
Closed access
GDGmhe Dackus
Gmhe Dackus
NHNd Ter Hoeve
Nd Ter Hoeve
MOM Opdam
M Opdam
WVW Vreuls
W Vreuls
EKEa Koop
Ea Koop
SLSc Linn
Sc Linn
This abstract was withdrawn by the authors.